Shock: Adrenomed AG gets FDA fast track designation
After Adrenomed AG has demonstrated that its septic shock treatment led to a 60% reduction in relative 28-day mortality vs. placebo in a stratified...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
AMPLY Discovery Ltd bags £1.4m funding to tackle complex diseases
The 2021 spin-out from the Queen’s University Belfast announced it will close a seed financing round this year.vAMPLY is speeding up the discovery of...
Seabelife SAS to develop next-gen dry AMD drug
French drug developer SeaBeLife SAS has bagged a €1.5m fund within the i-Nov 2024 innovation competition, which is part of the French government’s...
Scientists create non-digestible aptamer
The synthetic TNA nucleic acid analogues created by a biochemists at University of Cologne hrepresent a so called threofuranosyl nucleic acid...
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...